

APPENDIX – Glucocorticoid toxicity references

1. Smyllie HC, Connolly CK. Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. *Thorax*. 1968;23(6):571-581.
2. Fisher DE, Bickel WH. Corticosteroid-induced avascular necrosis. A clinical study of seventy-seven patients. *J Bone Joint Surg Am*. 1971;53(5):859-873.
3. Akingbehin AO. Corticosteroid-induced ocular hypertension. I. Prevalence in closed-angle glaucoma. *Br J Ophthalmol*. 1982;66(8):536-540.
4. Messer J, Reitman D, Sacks HS, Smith H, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. *N Engl J Med*. 1983;309(1):21-24.
5. Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. *J Allergy Clin Immunol*. 1985;76(2 Pt 1):234-242.
6. Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. *Lancet (London, England)*. 1987;1(8538):902-906.
7. Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). *Ann Rheum Dis*. 1988;47(9):733-739.
8. Patton PR, Pfaff WW. Aseptic bone necrosis after renal transplantation. *Surgery*. 1988;103(1):63-68.
9. Sooriyamoorthy M, Gower DB. Hormonal influences on gingival tissue: relationship to periodontal disease. *J Clin Periodontol*. 1989;16(4):201-208.
10. Vakil N, Sparberg M. Steroid-related osteonecrosis in inflammatory bowel disease. *Gastroenterology*. 1989;96(1):62-67.
11. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. *Am J Kidney Dis*. 1991;18(3):353-358.
12. Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. *Neurology*. 1991;41(8):1235-1239.
13. Hawthorne AB, Record CO, Holdsworth CD, et al. Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. *Gut*. 1993;34(1):125-128.
14. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. *Medicine (Baltimore)*. 1994;73(4):215-223.
15. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. *J Rheumatol*. 1994;21(7):1264-1267.
16. McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. *J Rheumatol*. 1994;21(7):1207-1213.
17. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. *Am J Med*. 1994;96(2):115-123.
18. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. *J Intern Med*. 1994;236(6):619-632.
19. Socié G, Sélimi F, Sedel L, et al. Avascular necrosis of bone after allogeneic bone

- marrow transplantation: clinical findings, incidence and risk factors. *Br J Haematol.* 1994;86(3):624-628.
20. Bradbury G, Benjamin J, Thompson J, Klees E, Copeland J. Avascular necrosis of bone after cardiac transplantation. Prevalence and relationship to administration and dosage of steroids. *J Bone Joint Surg Am.* 1994;76(9):1385-1388.
 21. Fryer JP, Granger DK, Leventhal JR, Gillingham K, Najarian JS, Matas AJ. Steroid-related complications in the cyclosporine era. *Clin Transplant.* 1994;8(3 Pt 1):224-229.
 22. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. *Transplantation.* 1995;60(9):1057-1060.
 23. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. *Transplantation.* 1996;62(11):1588-1592.
 24. Jindal RM, Sidner RA, Hughes D, et al. Metabolic problems in recipients of liver transplants. *Clin Transplant.* 1996;10(2):213-217.
 25. Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaladoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. *Neurology.* 1996;47(6):1396-1402.
 26. Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. A prospective study. *Psychoneuroendocrinology.* 1996;21(1):25-31.
 27. Stegall MD, Everson GT, Schroter G, et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. *Hepatology.* 1997;25(1):173-177.
 28. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. *Arthritis Rheum.* 1997;40(10):1873-1878.
 29. Akerkar GA, Peppercorn MA, Hamel MB, Parker RA. Corticosteroid-associated complications in elderly Crohn's disease patients. *Am J Gastroenterol.* 1997;92(3):461-464.
 30. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. *Neurology.* 1997;48(5):1234-1238.
 31. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. *Liver Transpl Surg.* 1998;4(4):285-296.
 32. Augustine SM, Baumgartner WA, Kasper EK. Obesity and hypercholesterolemia following heart transplantation. *J Transpl Coord.* 1998;8(3):164-169.
 33. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. *Gastroenterology.* 1998;115(4):835-840.
 34. Zabinski SJ, Sculco TP, Dicarlo EF, Rivelis M. Osteonecrosis in the rheumatoid femoral head. *J Rheumatol.* 1998;25(9):1674-1680.
 35. Lausten GS, Lemser T, Jensen PK, Egfjord M. Necrosis of the femoral head after kidney transplantation. *Clin Transplant.* 1998;12(6):572-574.
 36. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. *Lancet*

(London, England). 2000;355(9203):542-545.

37. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. *Arthritis Rheum*. 2000;43(8):1801-1808.
38. Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. *Lupus*. 2001;10(5):359-363.
39. Karagas MR, Cushing GL, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. *Br J Cancer*. 2001;85(5):683-686.
40. Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. *Am J Epidemiol*. 2001;153(11):1089-1093.
41. Nielsen GL, Sørensen HT, Mellekjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. *Am J Med*. 2001;111(7):541-545.
42. van Everdingen AA, Jacobs JWG, Siewertsz Van Reesema DR, Bijlsma JWJ. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. *Ann Intern Med*. 2002;136(1):1-12.
43. Brown ES, Suppes T, Khan DA, Carmody TJ. Mood changes during prednisone bursts in outpatients with asthma. *J Clin Psychopharmacol*. 2002;22(1):55-61.
44. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. *Arthritis Rheum*. 2003;49(5):703-708.
45. Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam L-S. Accrual of organ damage over time in patients with systemic lupus erythematosus. *J Rheumatol*. 2003;30(9):1955-1959.
46. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. *Arthritis Rheum*. 2003;48(11):3224-3229.
47. Kirwan JR, Hällgren R, Mielants H, et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. *Ann Rheum Dis*. 2004;63(6):688-695.
48. Bolanos SH, Khan DA, Hanczyc M, Bauer MS, Dhanani N, Brown ES. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. *Ann Allergy Asthma Immunol*. 2004;92(5):500-505.
49. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. *Osteoporos Int*. 2004;15(4):323-328.
50. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. *Heart*. 2004;90(8):859-865.
51. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Ann Intern Med*. 2004;141(10):764-770.
52. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. *Arthritis Rheum*. 2005;52(11):3360-3370.
53. Williams JJ, Lund LH, LaManca J, et al. Excessive weight gain in cardiac transplant

- recipients. *J Heart Lung Transplant*. 2006;25(1):36-41.
54. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. *Arthritis Rheum*. 2006;55(3):420-426.
 55. Da Silva JAP, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. *Ann Rheum Dis*. 2006;65(3):285-293.
 56. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. *Arthritis Rheum*. 2006;55(1):19-26.
 57. Maradit Kremers H, Reinalda MS, Crowson CS, Davis JM, Hunder GG, Gabriel SE. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. *Arthritis Rheum*. 2007;57(2):279-286.
 58. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. *Br J Dermatol*. 2007;157(1):142-148.
 59. Fardet L, Cabane J, Kettaneh A, Lebbé C, Flahault A. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. *Rheumatology (Oxford)*. 2007;46(7):1102-1106.
 60. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. *Rheumatology (Oxford)*. 2007;46(7):1157-1160.
 61. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. *Arthritis Rheum*. 2007;56(6):1754-1764.
 62. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. *Ann Rheum Dis*. 2007;66(3):308-312.
 63. De Vries F, Bracke M, Leufkens HGM, Lammers J-WJ, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. *Arthritis Rheum*. 2007;56(1):208-214.
 64. Varas-Lorenzo C, Rodriguez LAG, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. *Atherosclerosis*. 2007;192(2):376-383.
 65. Davis JM, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum*. 2007;56(3):820-830.
 66. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. *Arthritis Rheum*. 2008;58(9):2612-2621.
 67. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. *J Rheumatol*. 2008;35(3):387-393.
 68. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. *Arthritis Rheum*. 2008;59(8):1074-1081.
 69. Sosa M, Jódar E, Saavedra P, et al. Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes. *Eur J Intern Med*. 2008;19(1):51-56.
 70. Panoulas VF, Douglas KMJ, Stavropoulos-Kalinoglou A, et al. Long-term exposure to

- medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2008;47(1):72-75.
71. Lieberman JR, Roth KM, Elsisy P, Dorey FJ, Kobashigawa JA. Symptomatic osteonecrosis of the hip and knee after cardiac transplantation. *J Arthroplasty*. 2008;23(1):90-96.
 72. Shibatani M, Fujioka M, Arai Y, et al. Degree of corticosteroid treatment within the first 2 months of renal transplantation has a strong influence on the incidence of osteonecrosis of the femoral head. *Acta Orthop*. 2008;79(5):631-636.
 73. Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. *J Rheumatol*. 2009;36(3):560-564.
 74. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. *Ann Rheum Dis*. 2009;68(7):1119-1124.
 75. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. *Arch Intern Med*. 2009;169(18):1677-1683.
 76. Campbell S, Sun C-L, Kurian S, et al. Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation. *Cancer*. 2009;115(18):4127-4135.
 77. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. *Ann Rheum Dis*. 2010;69(2):380-386.
 78. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? *Ann Rheum Dis*. 2011;70(11):1914-1920.
 79. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor- α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. *JAMA*. 2011;306(21):2331-2339.
 80. Durand M, Thomas SL. Incidence of infections in patients with giant cell arteritis: a cohort study. *Arthritis Care Res (Hoboken)*. 2012;64(4):581-588.
 81. Dixon WG, Abrahamowicz M, Beauchamp M-E, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. *Ann Rheum Dis*. 2012;71(7):1128-1133.
 82. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. *BMJ*. 2012;345:e4928.
 83. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. *Am J Psychiatry*. 2012;169(5):491-497.
 84. Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. *Ann Rheum Dis*. 2013;72(8):1308-1314.
 85. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. *JAMA Intern Med*. 2013;173(9):743-752.
 86. Sadr-Azodi O, Mattsson F, Bexlius TS, Lindblad M, Lagergren J, Ljung R. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study. *JAMA Intern Med*. 2013;173(6):444-449.

87. Fardet L, Nazareth I, Whitaker HJ, Petersen I. Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. *J Clin Psychiatry*. 2013;74(4):e281-e286.
88. 100. del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. *Arthritis Rheumatol (Hoboken, NJ)*. 2014;66(2):264-272.
89. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF α inhibitors and rituximab. *Ann Rheum Dis*. 2015;74(2):415-421
90. Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC. High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review. *J Arthroplasty*. 2015;30(9):1506-1512.e5.
91. Lake KD, Reutzel TJ, Pritzker MR, Jorgensen CR, Emery RW. The impact of steroid withdrawal on the development of lipid abnormalities and obesity in heart transplant recipients. *J Heart Lung Transplant*. 12(4):580-590.
92. Taylor DO, Thompson JA, Hastillo A, et al. Hyperlipidemia after clinical heart transplantation. *J Heart Transplant*. 8(3):209-213; discussion 219-220.
93. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. *Rev Infect Dis*. 11(6):954-963.
94. Zazzali JL, Broder MS, Omachi TA, Chang E, Sun GH, Raimundo K. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. *Allergy Asthma Proc*. 36(4):268-274.
95. Renedo RJG, Sousa MM, Pérez SF, Zabalbeascoa JR, Carro LP. Avascular necrosis of the femoral head in patients with Hodgkin's disease. *Hip Int*. 20(4):473-481.
96. van der Goes MC, Jacobs JWG, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis*. 2010;69(6):1015-1021.